Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles
| العنوان: | Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles |
|---|---|
| المؤلفون: | Anwar R. Padhani, N C Levitt, S Mehta, N P Hughes, Sonia P. Li, Andreas Makris, R F Adams, A Adwani, Francesca M. Buffa, NJ Taylor, Adrian L. Harris |
| المصدر: | JNCI Monographs |
| بيانات النشر: | Oxford University Press (OUP), 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Gadolinium DTPA, Vascular Endothelial Growth Factor A, Oncology, Cancer Research, medicine.medical_specialty, Pathology, Bevacizumab, Contrast Media, Angiogenesis Inhibitors, Breast Neoplasms, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Predictive Value of Tests, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Gene expression, Biomarkers, Tumor, medicine, Medical imaging, Humans, 030304 developmental biology, 0303 health sciences, medicine.diagnostic_test, business.industry, Gene Expression Profiling, Biopsy, Needle, Cancer, Magnetic resonance imaging, General Medicine, medicine.disease, Magnetic Resonance Imaging, Neoadjuvant Therapy, 3. Good health, Gene Expression Regulation, Neoplastic, Gene expression profiling, Receptors, Vascular Endothelial Growth Factor, Treatment Outcome, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Primary breast cancer, business, medicine.drug |
| الوصف: | Antiangiogenic therapy is a promising approach for the treatment of breast cancer. In practice, however, only a subset of patients who receive antiangiogenic drugs demonstrate a significant response. A key challenge, therefore, is to discover biomarkers that are predictive of response to antiangiogenic therapy. To address this issue, we have designed a window-of-opportunity study in which bevacizumab is administered as a short-term first-line treatment to primary breast cancer patients. Central to our approach is the use of a detailed pharmacodynamic assessment, consisting of pre- and post-bevacizumab multi-parametric magnetic resonance imaging scans and core biopsies for exon array gene expression analysis. Here, we illustrate three intrinsic patterns of response to bevacizumab and discuss the molecular mechanisms that may underpin each. Our results illustrate how the combination of dynamic imaging data and gene expression profiles can guide the development of biomarkers for predicting response to antiangiogenic therapy. J Natl Cancer Inst Monogr 2011;43:71–74 |
| تدمد: | 1745-6614 1052-6773 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::047747ff69b47c1ea95fa2f377d6503f https://doi.org/10.1093/jncimonographs/lgr027 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....047747ff69b47c1ea95fa2f377d6503f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17456614 10526773 |
|---|